Qualcomm’s Capsule receives FDA clearance of SmartLinx Vitals Plus

Qualcomm announced that Capsule, a wholly owned subsidiary of Qualcomm Life, has received FDA 510(k) clearance of SmartLinx Vitals Plus, an innovative patient monitoring system that uniquely integrates vital signs monitoring and clinical documentation into one scalable platform. SmartLinx Vitals Plus, part of Capsule's SmartLinx Medical Device Information System, is a powerful alternative to traditional low acuity monitors. It provides new functionality in a single platform that allows hospitals and other health care facilities to streamline user authentication, patient identification, vitals measurement, and clinical documentation by integrating vital signs modules and components directly to the SmartLinx Neuron [TM] 2 mobile clinical computer.

"Today's patient bedside is crowded with technology used to capture, chart and review the complete set of patient vitals, and we see tremendous opportunity in technological convergence – the ability to combine these multiple components into a single device or 'all-in-one' solution requiring one workflow," said Kevin Phillips, vice president, marketing and product management, Capsule. "In SmartLinx Vitals Plus, we developed a fully integrated mobile system that streamlines the patient monitoring and clinical documentation process through a clinician-friendly, flexible workflow – complete with an early warning scoring system – that presents vitals data all on one screen, right at the point-of-care."

To continue reading this article…

Start your monthly or annual subscription to HIT Leaders & News today!

A monthly Standard subscription to all our regular news articles costs only $12.00 per month, or $144.00 for an annual Standard subscription.

Already a subscriber? Log in


Capsule, FDA, Qualcomm, SmartLinx Neuron, SmartLinx Vitals Plus


Please follow and ‘Like’ us


©2021 HIT Leaders and News, a GO Digital Media publication. All rights reserved.